Avoid common mistakes on your manuscript.
Correction to: Adv Ther (2022) 39:4910–4960 https://doi.org/10.1007/s12325-022-02281-4
On page 4913 in Table 1 under the topic Rheumatoid arthritis, Sex, the percentage female is stated to be 69–81%.
The entry should read as follows: “Female 69–82% [20, 21]”
On page 4913 in Table 1 under the topic Rheumatoid arthritis, Risk of infection, the entry is: “Increased [45]; IRh of 19.64/100 PY and 32.05/100 PY [46]”.
The entry should read as follows: “Increased [45]; IR of 19.64–87.7/100 PY [46, 48]h”
On page 4913 in Table 1 under the topic Rheumatoid arthritis, Risk of infection, the entry is: “Serious infection IR of 1.5–87.7/100 PY [46–48]i”.
The entry should read as follows: “Serious infection IR of 1.5–12.1/100 PY [46–48]i”
On page 4913 in Table 1 under the topic Rheumatoid arthritis, Risk of MACE, the entry is: “Increased [32]; IR of 0.27–3/2/100 PY [57–60]”.
The entry should read as follows: “Increased [32]; IR of 0.27–3.2/100 PY [57–60]”
On page 4913 in Table 1 under the topic Rheumatoid arthritis, Risk of malignancy, the SIR for melanoma is stated to be 1.3.
The entry should read as follows: “Increased [81–83]; by 10% overall versus general population [81] (lymphoma SIR 2.46], lung [SIR 1.64], melanoma [SIR 1.23) [81]”
On page 4913 in Table 1 under the topic Rheumatoid arthritis, Risk of GI perforation, reference 90 is incorrectly cited.
The entry should read as follows: “Increased; IR 0.17/100 PY (IR 0.14/100 PY for the lower GI tract) [89]”
On page 4914 in Table 1 under footnote h, the entry is: “Objectively confirmed infections and physician-documented infections, respectively in a US cohort study of adult patients with RA [46]”.
The entry should read as follows: “Objectively confirmed infections (IR 19.64/100 PY) and physician-documented infections (IR 32.05/100 PY) in a US cohort study of adult patients with RA [46] and all infections reported in a retrospective cohort analysis of patients all treated with DMARDs (77.4–87.7/100 PY) [48].”
On page 4914 in Table 1 under footnote i, the entry is: “Range for SIs (i.e. requiring hospitalisation or intravenous antibiotics) reported in RCTs and their long-term extension studies, and RWE from patient registries in patients with RA (IR 1.5–7/100 PY) [47], SIs (defined as infections requiring hospitalisation in a general RA population) (IR 9.57/100 PY) [46] and a retrospective cohort analysis of patients all treated with DMARDs (77.4 to 87.7/100 PY) [48]”.
The entry should read as follows: “Range for serious infections (i.e., requiring hospitalisation or intravenous antibiotics) reported in RCTs and their long-term extension studies, and RWE from patient registries in patients with RA (IR 1.5–7/100 PY) [47], serious infections (defined as infections requiring hospitalisation) in a general RA population (IR 9.57/100 PY) [46] and serious infections (i.e., requiring hospitalisation or intravenous antibiotics) in a retrospective cohort analysis of patients all treated with DMARDs (8.9–12.1/100 PY) [48].”
On page 4918 in Table 2 under the topic Atopic dermatitis, BREEZE-AD4 (NCT03428100), Study cohort, the percentage female is stated to be 34%.
The entry should read as follows: “36% female”
On page 4921 in Table 2 under the topic Other, Autoimmune interferonopathies clinical trial, Study cohort, the percentage female is stated to be 37%.
The entry should read as follows: “33% female”
On page 4929 in Table 3 in the title, reference 111 is missing.
The entry should read as follows: “Incidence rate (95% confidence interval) of infections in patients treated with baricitinib in the placebo-controlled periods of clinical trials and the All baricitinib data set (integrated safety database results [91, 99, 104, 107, 111]) by disease being treated”
On page 4934 in Fig. 2 under the topic SLE, IR per 100 patient-years reported in patients with the respective disease, reference 65 is cited instead of the correct reference 79.
The entry should read as follows: “0.52–1.85 [74, 78–80]”
On page 4935 under the topic Disease-Specific Risk of VTE in SLE, in the first sentence, reference 81 is cited instead of the correct reference 79.
The sentence should read as follows: “The risks of VTE, PE and DVT are increased in patients with SLE (Fig. 2; Table 1) [74, 79, 80, 171, 175, 176], and higher than that in patients with RA in database analyses [74, 175, 177].”
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Bieber, T., Feist, E., Irvine, A.D. et al. Correction to: A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19. Adv Ther 40, 4114–4115 (2023). https://doi.org/10.1007/s12325-023-02526-w
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-023-02526-w